Curi Bio, a Seattle-based biotechnology company, has announced the launch of a new subsidiary, Curi Bio Co., which will serve as its commercial and operational hub for the Asia-Pacific region.
In a news release issued Monday, the company said the move follows its acquisition of South Korea-based Quvit Bio and is designed to further expand Curi Bio’s presence and capabilities in Asia so it can better serve its growing regional customer base.
“Curi Bio Co. represents a day-one ready sales, R&D and operational hub, allowing us to directly serve the APAC market. We can now offer localized technical and sales support for our existing customer base across South Korea, Japan and China while lowering the access barrier to Curi’s industry-leading NAM technology for all drug developers in the region,” Nicholas Geisse, CEO of Curi Bio, said in a statement.
Geisse added that the new hub will enable faster and more reliable delivery of the company’s cells, media, hardware and consumables by reducing delays associated with international logistics, helping the company bring its therapies to global markets more efficiently.
